This is because early‐stage lesions often present with non‐specific clinical and imaging features, making it imperative that any proposed biomarker demonstrates robust performance across diverse populations in distinguishing early HCC from benign liver conditions (such as “Cirrhosis no HCC” controls, similar to the stratified analysis we performed for SF3B4 in the Figure 5C) through rigorous multi‐center validation before any clinical application need to be considered in future. Here, SF3B4 is linked to Cirrhosis.